Benjamin L. Hoch, M.D.

photo of Benjamin Hoch

Professor

Email: bhoch@salud.unm.edu


Interests:

  • Surgical Pathology: Improving diagnostic quality and accuracy, cost effective practices, predicting outcome and response to therapy in neoplastic diseases
  • Bone Pathology: Pathological-radiological correlation, improving diagnostic accuracy of cartilage neoplasms, cost effective utilization of ancillary studies
  • Soft Tissue Pathology: Understanding pathogenesis and identifying prognostic and predictive markers in liposarcomas, cost effective utilization of ancillary molecular studies
  • Head and Neck Pathology: Bone and soft tissue tumors of the head and neck, diagnostic accuracy of squamous proliferations and salivary gland tumors
  • Role of Pathologist in Patient Care and Health Care Systems: Evolving role and unique value of pathology in the health care system, patient and family centered care, interfacing pathology with other fields of study

Education and Certification Information

Fellowship:
Benjamin Castleman Fellow in Surgical Pathology, Bone and Soft Tissue Pathology, and Head and Neck Pathology (2002-2003)
Massachusetts General Hospital and Harvard Medical School, Boston, MA

Residency:
Anatomic Pathology (1999-2002)
Washington University/Barnes-Jewish Hospital, St. Louis, MO

Medical School:
Jefferson Medical College of Thomas Jefferson University (1995-1999)

Board Certifications:
American Board of Pathology – Anatomic Pathology (2003)

Specialties:
Bone Pathology
Soft Tissue Pathology
Head and Neck Pathology


Selected Publications:

  1. Ricciotti R, Baraff AJ, Jour G, Kyriss M, WuY, LiuY, Li SC, Hoch B (co-senior author), Liu YJ. High Amplification Levels of MDM2 and CDK4 Correlate with Poor Outcome in Patients with Dedifferentiated Liposarcoma: A Cytogenomic Microarray Analysis of 47 Cases. Cancer Genetics 2017; 218:69-80.

  2. Pollack S, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty V, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL. T-Cell infiltration and clonality correlate with programmed cell death protein 1 and program death-ligand 1expression in patients with soft tissue sarcomas. Cancer 2017;123:3291-3304.

  3. Jour G, Liu Y, Ricciotti R, Pritchard C, Hoch BL. Glandular differentiation in dedifferentiated chondrosarcoma: molecular evidence of a rare phenomenon. Human Pathology 2015;46(9):1398-1404.

  4. Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty V, Hoch BL, Gullet A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C. Tetramer guided cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T-cells. J Immunother Cancer 2014;2(1):36.

  5. Jour G, Oda D, Hoch B. Metastatic alveolar soft part sarcoma to the posterior mandible as initial presentation: a first report of an extremely uncommon scenario. J of Oral and Maxillofacial Surg Med Pathol (JOMSMP) 2015;27(3);438-441.

  6. Jour G, Gullet A, Liu M, Hoch B. Prognostic relevance of Federation Nationale des Centres de Lutte Contre le Cancer grading and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. Modern Pathology 2015;28:27-47.

  7. Jour G, Scarborough JD, Jones, RL, Loggers E, Pollack SM, Pritchard CC, Hoch B. Molecular profiling of soft tissue tumors using next-generation sequencing: a pilot study towards precision therapeutics. Human Pathology 2014;45(8):1563-1571.

  8. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/ round cell liposarcoma. Cancer 2012;118(18):4564-4570.

  9. Borys D, Canter RJ. Hoch B, Martinez SR, Tamurian RM, Murphy B, Bishop JW, Horvai A. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy. Human Pathology 2012;43(11):1948-1954.

  10. Camacho-Vanegas O, Camacho SC, Till, J, Miranda-Lorenzo I, Terzo E, Ramirez MC, Schramm V, Cordovano G, Watts G, Mehta S, Kimonis V, Hoch B, Philibert KD, Raabe CA, Bishop DF, Glucksman MJ, Martignetti JA. Primate genome gain and loss: An autosomal dominant bone dysplasia/muscular dystrophy/bone cancer syndrome resulting from mutation of retroviral-derived MTAP transcripts. American Journal of Human Genetics 2012;90:614-627.

  11. Hoch BL, Wu M, Lewis M, Genden E, Burstein DE. An immunohistochemical study of XIAP expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma. J Oral Pathol Med 2008;37(10):634-638.

  12. Hoch BL, Inwards C, Sundaram M, Rosenberg AE. Multicentric giant cell tumor of bone: a clinicopathologic analysis of 30 cases. J Bone Joint Surg Am 2006;88:1998-2008.

  13. Hoch BL, Nielsen GP, Liebsch NJ, Rosenberg AE. Base of skull chordomas in children and adolescents: a clinicopathologic analysis of 72 cases. Am J Surg Path 2006;30(7):811-818.